[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625432":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":26,"responsibleParty":41,"collaborators":26,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":26,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":26,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":26,"overallStatus":64,"whyStopped":26,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":26},{"fullName":5,"class":6},"Hayatabad Medical Complex","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nalbupine group","EXPERIMENTAL","Patient recieving intravenous nalbuphine prior to propofol induction",[13],"Drug: Nalbuphine",{"label":15,"type":16,"description":17,"interventionNames":18},"Lidocaine group","ACTIVE_COMPARATOR","Patient recieving intravenous lidocaine prior to propofol induction",[19],"Drug: Lidocaine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Nalbuphine","Intravenous nalbuphine 0.1mg\u002Fkg administred 60second prior to induction with propofol",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Lidocaine","Intravenous lidocaine 4.5mg\u002Fkg (maximum 300mg) administred 60sec prior to induction with propofol",[15],[32],{"name":33,"affiliation":34,"role":35},"Dr.Arina kore Trainee medical officer, MBBS","PGMI\u002FHayatabad Medical complex(HMC),Peshawar","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","+923446835431","Kore2k15@gmail.com",{"type":35,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Amina Sultan","Assistant professor","100625432","intravenous-nalbuphine-versus-lidocaine-for-prevention-of-propofol-injection-pain-100625432",false,"NCT07422558","Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain","Comprasion of Intravenous Nalbuphine Versus Lidocaine in Reducing Propofol -Induced Injection Pain During General Surgery Procedure","Inclusion Criteria:\n\n* Age 18-60 years\n\n  * Either male or female\n  * ASA physical status I or II\n  * Scheduled for elective general surgery under general anesthesia using propofol\n\nExclusion Criteria:\n\n* Known hypersensitivity to propofol, nalbuphine, or lidocaine\n\n  * Emergency surgery\n  * Use of analgesics prior to surgery\n  * Pregnant women\n  * Lactating women",true,"ALL","18 Years","60 Years",{"count":56,"type":57},92,"ESTIMATED","INTERVENTIONAL",[60],"NA","Propofol is a commonly used intravenous anesthetic agent, but its administration is frequently associated with injection pain, causing patient discomfort and agitation. Various pharmacological agents have been used to reduce this pain, including nalbuphine and lidocaine; however, results from previous studies remain conflicting. This randomized clinical trial aims to compare the effectiveness of intravenous nalbuphine versus intravenous lidocaine in reducing the frequency of propofol-induced injection pain in patients undergoing elective general surgery procedures.",[63],"Procedural Pain","NOT_YET_RECRUITING","2026-02-13",{"date":67,"type":68},"2026-02-20","ACTUAL",{"date":70,"type":57},"2026-03-01",{"date":72,"type":57},"2026-08-01",{"name":5,"class":6}]